董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Ford | 男 | Chairman of the Board and Chief Executive Officer and Director | 49 | 2172.22万美元 | 37.87 | 2023-09-01 |
| Daniel J. Starks | 男 | Director | 69 | 32.43万美元 | 672.56 | 2023-09-01 |
| John G. Stratton | 男 | Director | 63 | 31.70万美元 | 1.55 | 2023-09-01 |
| Sally E. Blount | 女 | Director | 62 | 34.07万美元 | 3.32 | 2023-09-01 |
| Darren W. McDew | 男 | Director | 63 | 31.10万美元 | 0.69 | 2023-09-01 |
| Michelle A. Kumbier | 女 | Director | 56 | 31.70万美元 | 1.22 | 2023-09-01 |
| Paola Gonzalez | -- | Director | 52 | 31.70万美元 | 0.34 | 2023-09-01 |
| Claire Babineaux Fontenot | 男 | Director | 59 | 3.15万美元 | 0.18 | 2023-09-01 |
| Robert J. Alpern | 男 | Director | 73 | 37.22万美元 | 3.73 | 2023-09-01 |
| William A. Osborn | 男 | Director | 76 | 34.10万美元 | 未持股 | 2023-09-01 |
| Glenn F. Tilton | 男 | Director | 76 | 35.77万美元 | 未持股 | 2023-09-01 |
| Nancy McKinstry | 女 | Director | 65 | 33.60万美元 | 3.52 | 2023-09-01 |
| Michael F. Roman | 男 | Director | 64 | 31.70万美元 | 0.50 | 2023-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert Ford | 男 | Chairman of the Board and Chief Executive Officer and Director | 49 | 2172.22万美元 | 37.87 | 2023-09-01 |
| Daniel Salvadori | 男 | Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products | 44 | 715.77万美元 | 11.99 | 2023-09-01 |
| Jared L. Watkin | 男 | Senior Vice President, Diabetes Care | 55 | 未披露 | 未持股 | 2023-09-01 |
| Joseph Manning | -- | Executive Vice President, Nutritional Products | 54 | 未披露 | 未持股 | 2023-09-01 |
| Sammy Karam | -- | Senior Vice President, Established Pharmaceuticals, Emerging Markets | 61 | 未披露 | 未持股 | 2023-09-01 |
| Michael J. Pederson | -- | Senior Vice President, Electrophysiology | 61 | 未披露 | 未持股 | 2023-09-01 |
| Alejandro D. Wellisch | -- | Senior Vice President, Established Pharmaceuticals, Latin America | 48 | 未披露 | 未持股 | 2023-09-01 |
| John F. Ginascol | -- | Executive Vice President, Core Diagnostics | 64 | 520.85万美元 | 未持股 | 2023-09-01 |
| Mary K. Moreland | -- | Executive Vice President, Human Resources | 56 | 未披露 | 未持股 | 2023-09-01 |
| Andrea Wainer | -- | Executive Vice President, Rapid and Molecular Diagnostics | 54 | 628.71万美元 | 未持股 | 2023-09-01 |
| Michael D. Dale | -- | Senior Vice President, Structural Heart | 63 | 未披露 | 未持股 | 2023-09-01 |
| Randel W. Woodgrift | -- | Senior Vice President, Cardio Rhythm Management | 61 | 未披露 | 未持股 | 2023-09-01 |
| Gregory A. Ahlberg | -- | Senior Vice President, Core Laboratory Diagnostics, Commercial Operations | 56 | 未披露 | 未持股 | 2023-09-01 |
| Philip P. Boudreau | -- | Senior Vice President, Finance and Chief Financial Officer | 50 | 未披露 | 1.84 | 2023-09-01 |
| Christopher J. Calamari | 女 | Senior Vice President, U.S. Nutrition | 52 | 未披露 | 未持股 | 2023-09-01 |
| Fernando Mateus | -- | Senior Vice President, International Nutrition | 48 | 未披露 | 未持股 | 2023-09-01 |
| Louis H. Morrone | -- | Senior Vice President, Rapid Diagnostics | 46 | 未披露 | 未持股 | 2023-09-01 |
| Julie L. Tyler | -- | Senior Vice President, Abbott Vascular | 53 | 未披露 | 未持股 | 2023-09-01 |
| John A. McCoy, Jr. | 男 | Vice President, Controller | 53 | 未披露 | 未持股 | 2023-09-01 |
| John M. Capek | -- | Executive Vice President, Ventures | 61 | 376.59万美元 | 未持股 | 2023-09-01 |
| Hubert L. Allen | -- | Executive Vice President, General Counsel and Secretary | 57 | 701.96万美元 | 17.60 | 2023-09-01 |
| Robert E. Funck | -- | Executive Vice President, Finance | 61 | 914.52万美元 | 25.74 | 2023-09-01 |
| Lisa D. Earnhardt | 女 | Executive Vice President, Medical Devices | 53 | 729.52万美元 | 7.54 | 2023-09-01 |
董事简历
中英对照 | 中文 | 英文- Robert Ford
-
Robert Ford，担任执行副总裁，负责医疗设备（2015年至今）、高级副总裁，负责糖尿病护理（2014年至2015年）、糖尿病护理贸易化运营副总裁（2008年至2014年）、公司职员（2008年）。
Robert Ford,Chairman of the Board and Chief Executive Officer of Abbott since December 2021.President and Chief Executive Officer of Abbott from March 2020 to December 2021.President and Chief Operating Officer of Abbott from 2018 to 2020.Executive Vice President, Medical Devices of Abbott from 2015 to 2018.Senior Vice President, Diabetes Care of Abbott from 2014 to 2015.Held various leadership roles across Abbott's Diagnostics, Nutrition, and Diabetes Care businesses in the U.S. and Latin America since joining Abbott in 1996. - Robert Ford，担任执行副总裁，负责医疗设备（2015年至今）、高级副总裁，负责糖尿病护理（2014年至2015年）、糖尿病护理贸易化运营副总裁（2008年至2014年）、公司职员（2008年）。
- Robert Ford,Chairman of the Board and Chief Executive Officer of Abbott since December 2021.President and Chief Executive Officer of Abbott from March 2020 to December 2021.President and Chief Operating Officer of Abbott from 2018 to 2020.Executive Vice President, Medical Devices of Abbott from 2015 to 2018.Senior Vice President, Diabetes Care of Abbott from 2014 to 2015.Held various leadership roles across Abbott's Diagnostics, Nutrition, and Diabetes Care businesses in the U.S. and Latin America since joining Abbott in 1996.
- Daniel J. Starks
-
Daniel J. Starks，曾担任St. Jude Medical, Inc.的董事长、总裁和首席执行官（2004年至2016年1月退休），随后担任董事会执行主席，直到2017年1月Abbott完成了对St. Jude Medical, Inc.的收购。他也曾担任St. Jude Medical, Inc.的总裁兼首席运营官（2001年至2004年），以及其总裁兼首席执行官，负责心脏节律管理业务（1997年至2001年）。
Daniel J. Starks,Executive Chairman of the Board of St. Jude Medical, Inc., a medical device manufacturer, from January 2016 to January 2017, when Abbott completed its acquisition of St. Jude Medical.Chairman, President and Chief Executive Officer of St. Jude Medical from 2004 until his retirement in January 2016.President and Chief Operating Officer of St. Jude Medical from 2001 to 2004.President and CEO, Cardiac Rhythm Management Business of St. Jude Medical from 1997 to 2001. Having served as St. Jude Medical's Executive Chairman and its Chairman, President and Chief Executive Officer, and having joined St. Jude Medical in 1996, Mr. Starks contributes not only comprehensive and critical knowledge of St. Jude Medical's operations, but also extensive business and management experience operating a global public company in a highly regulated industry. - Daniel J. Starks，曾担任St. Jude Medical, Inc.的董事长、总裁和首席执行官（2004年至2016年1月退休），随后担任董事会执行主席，直到2017年1月Abbott完成了对St. Jude Medical, Inc.的收购。他也曾担任St. Jude Medical, Inc.的总裁兼首席运营官（2001年至2004年），以及其总裁兼首席执行官，负责心脏节律管理业务（1997年至2001年）。
- Daniel J. Starks,Executive Chairman of the Board of St. Jude Medical, Inc., a medical device manufacturer, from January 2016 to January 2017, when Abbott completed its acquisition of St. Jude Medical.Chairman, President and Chief Executive Officer of St. Jude Medical from 2004 until his retirement in January 2016.President and Chief Operating Officer of St. Jude Medical from 2001 to 2004.President and CEO, Cardiac Rhythm Management Business of St. Jude Medical from 1997 to 2001. Having served as St. Jude Medical's Executive Chairman and its Chairman, President and Chief Executive Officer, and having joined St. Jude Medical in 1996, Mr. Starks contributes not only comprehensive and critical knowledge of St. Jude Medical's operations, but also extensive business and management experience operating a global public company in a highly regulated industry.
- John G. Stratton
-
John G. Stratton于2015年2月至2018年12月担任Verizon Communications Inc.执行副总裁兼全球运营总裁。此前，他曾于2014年4月至2015年2月担任执行副总裁兼全球企业和消费者有线业务总裁，2012年1月至2014年4月担任Verizon企业解决方案总裁，2010年10月至2012年1月担任Verizon Wireless首席运营官兼执行副总裁。斯特拉顿先生目前在通用动力公司董事会任职。2012年10月至2018年7月，斯特拉顿先生还担任总统国家安全电信咨询委员会成员，2015年2月至2018年7月，他还担任蜂窝通信行业协会理事。
John G. Stratton,Executive Chairman of Frontier Communications Parent, Inc. since April 2021.Executive Vice President and President of Global Operations, Verizon Communications, Inc., 2015 to 2018; Executive Vice President of Global Enterprise and Consumer Wireline, 2014 to 2015; Executive Vice President and President of Verizon Enterprise, 2012 to 2014; Executive Vice President and Chief Operating Officer of Verizon Wireless, 2010 to 2012.Mr. Stratton currently serves as Executive Chairman of the Board of Frontier Communications Parent, Inc.; he also currently serves as a director of Abbott Laboratories since 2017. - John G. Stratton于2015年2月至2018年12月担任Verizon Communications Inc.执行副总裁兼全球运营总裁。此前，他曾于2014年4月至2015年2月担任执行副总裁兼全球企业和消费者有线业务总裁，2012年1月至2014年4月担任Verizon企业解决方案总裁，2010年10月至2012年1月担任Verizon Wireless首席运营官兼执行副总裁。斯特拉顿先生目前在通用动力公司董事会任职。2012年10月至2018年7月，斯特拉顿先生还担任总统国家安全电信咨询委员会成员，2015年2月至2018年7月，他还担任蜂窝通信行业协会理事。
- John G. Stratton,Executive Chairman of Frontier Communications Parent, Inc. since April 2021.Executive Vice President and President of Global Operations, Verizon Communications, Inc., 2015 to 2018; Executive Vice President of Global Enterprise and Consumer Wireline, 2014 to 2015; Executive Vice President and President of Verizon Enterprise, 2012 to 2014; Executive Vice President and Chief Operating Officer of Verizon Wireless, 2010 to 2012.Mr. Stratton currently serves as Executive Chairman of the Board of Frontier Communications Parent, Inc.; he also currently serves as a director of Abbott Laboratories since 2017.
- Sally E. Blount
-
Sally E. Blount，她是芝加哥教区天主教慈善机构的首席执行官，也是西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University） 2010-2018年的前任院长。她目前任职于Abbott Laboratories、the Joyce Foundation和the Economic Club of Chicago的董事会。她也是阿斯彭研究所商业和社会项目和芝加哥金融委员会的顾问委员会成员。她拥有15年的西北大学（Northwestern university）和纽约大学（New York university）商学院院长和高级大学管理人员的经验，以及30多年的西北大学凯洛格商学院（Kellogg school）本科、MBA、博士和高管级别的商业教育家经验。纽约大学斯特恩商学院（Stern School of Business）和芝加哥大学布斯商学院（University of Chicago Booth School of Business）。在职业生涯早期，她曾担任Eva Maddox Associates（现为Perkins + Will的一部分）的财务和规划总监，以及波士顿咨询集团（Boston Consulting Group）的副顾问。
Sally E. Blount,President and Chief Executive Officer of Catholic Charities of the Archdiocese of Chicago since August 2020.Michael L. Nemmers Professor of Strategy at the J.L. Kellogg Graduate School of Management at Northwestern University since 2010.Dean of the J.L. Kellogg Graduate School of Management at Northwestern University from 2010 to 2018.Dean of the New York University Undergraduate College and Vice Dean of its Leonard N. Stern School of Business from 2004 to 2010.Professor at the New York University Leonard School of Business from 2001 to 2010, and became the Abraham L. Gitlow Professor of Management in 2004.Held academic posts at the University of Chicago's Graduate School of Business from 1992 to 2001.Serves on the Board of Directors of the Joyce Foundation and Economic Club of Chicago.Served on the Board of Directors of Ulta Beauty, Inc. from 2017 to 2022. - Sally E. Blount，她是芝加哥教区天主教慈善机构的首席执行官，也是西北大学凯洛格管理学院（Kellogg School of Management at Northwestern University） 2010-2018年的前任院长。她目前任职于Abbott Laboratories、the Joyce Foundation和the Economic Club of Chicago的董事会。她也是阿斯彭研究所商业和社会项目和芝加哥金融委员会的顾问委员会成员。她拥有15年的西北大学（Northwestern university）和纽约大学（New York university）商学院院长和高级大学管理人员的经验，以及30多年的西北大学凯洛格商学院（Kellogg school）本科、MBA、博士和高管级别的商业教育家经验。纽约大学斯特恩商学院（Stern School of Business）和芝加哥大学布斯商学院（University of Chicago Booth School of Business）。在职业生涯早期，她曾担任Eva Maddox Associates（现为Perkins + Will的一部分）的财务和规划总监，以及波士顿咨询集团（Boston Consulting Group）的副顾问。
- Sally E. Blount,President and Chief Executive Officer of Catholic Charities of the Archdiocese of Chicago since August 2020.Michael L. Nemmers Professor of Strategy at the J.L. Kellogg Graduate School of Management at Northwestern University since 2010.Dean of the J.L. Kellogg Graduate School of Management at Northwestern University from 2010 to 2018.Dean of the New York University Undergraduate College and Vice Dean of its Leonard N. Stern School of Business from 2004 to 2010.Professor at the New York University Leonard School of Business from 2001 to 2010, and became the Abraham L. Gitlow Professor of Management in 2004.Held academic posts at the University of Chicago's Graduate School of Business from 1992 to 2001.Serves on the Board of Directors of the Joyce Foundation and Economic Club of Chicago.Served on the Board of Directors of Ulta Beauty, Inc. from 2017 to 2022.
- Darren W. McDew
-
Darren W. McDew是一名退休的四星上将，在美军服役36年，2018年10月退休。2015年8月至2018年8月，McDew将军担任美国运输司令部司令，是美国国防部全球空运、陆运和海运的唯一管理者。此前，他还担任参谋长联席会议战略计划和政策副主任、总统军事助理、空军公共事务主任和空军参议院联络处处长。McDew将军目前在帕森斯公司、劳斯莱斯、北美公司、联合服务汽车协会和美国男孩女孩俱乐部的董事会任职。
Darren W. Mcdew,Four-star general who served for 36 years in the United States military before retiring in October 2018.Commander, U.S. Transportation Command, the single manager for global air, land and sea transportation for the U.S. Department of Defense from 2015 to 2018.Held various leadership roles across the U.S. Military, including Vice Director for Strategic Plans and Policy for the Joint Chiefs of Staff, Military Aide to the President, Director of Air Force Public Affairs, and Chief of Air Force Senate Liaison Division.Serves on the Board of Directors of United Services Automobile Association, Boys & Girls Club of America, and Manns Home Youth Foundation. - Darren W. McDew是一名退休的四星上将，在美军服役36年，2018年10月退休。2015年8月至2018年8月，McDew将军担任美国运输司令部司令，是美国国防部全球空运、陆运和海运的唯一管理者。此前，他还担任参谋长联席会议战略计划和政策副主任、总统军事助理、空军公共事务主任和空军参议院联络处处长。McDew将军目前在帕森斯公司、劳斯莱斯、北美公司、联合服务汽车协会和美国男孩女孩俱乐部的董事会任职。
- Darren W. Mcdew,Four-star general who served for 36 years in the United States military before retiring in October 2018.Commander, U.S. Transportation Command, the single manager for global air, land and sea transportation for the U.S. Department of Defense from 2015 to 2018.Held various leadership roles across the U.S. Military, including Vice Director for Strategic Plans and Policy for the Joint Chiefs of Staff, Military Aide to the President, Director of Air Force Public Affairs, and Chief of Air Force Senate Liaison Division.Serves on the Board of Directors of United Services Automobile Association, Boys & Girls Club of America, and Manns Home Youth Foundation.
- Michelle A. Kumbier
-
Michelle A. Kumbier于2017年10月至2020年4月担任哈雷戴维森汽车公司前首席运营官。Kumbier女士曾于2015年5月至2017年10月担任哈雷戴维森汽车公司产品和运营高级副总裁，2012年9月至2015年4月担任哈雷戴维森摩托车运营高级副总裁，2010年11月至2012年8月担任哈雷戴维森产品开发高级副总裁。她的职业生涯始于1997年任职Harley-Davidson公司。加入Harley-Davidson之前，Kumbier女士于1986年在科勒公司工作，在那里她在管道产品和发动机部门担任过各种职位。Kumbier女士自2018年起担任雅培实验室董事会成员。Kumbier女士是Teledyne Technologies Incorporated审计委员会和人事与薪酬委员会的成员。
Michelle A. Kumbier,Senior Vice President and President, Turf & Consumer Products of Briggs & Stratton, LLC, a manufacturer and marketer of engines, batteries, and outdoor power equipment, since March 2022.Senior Vice President and Chief Operating Officer of Harley-Davidson Motor Company, a motorcycle and related products manufacturer, from 2017 to 2020.Senior Vice President of Motor Company Product and Operations of Harley-Davidson from 2015 to 2017.Held various other executive roles across Harley-Davidson, from 1997 to 2015.Held various positions at Kohler Company, maker of premium plumbing products, from 1986 to 1997. - Michelle A. Kumbier于2017年10月至2020年4月担任哈雷戴维森汽车公司前首席运营官。Kumbier女士曾于2015年5月至2017年10月担任哈雷戴维森汽车公司产品和运营高级副总裁，2012年9月至2015年4月担任哈雷戴维森摩托车运营高级副总裁，2010年11月至2012年8月担任哈雷戴维森产品开发高级副总裁。她的职业生涯始于1997年任职Harley-Davidson公司。加入Harley-Davidson之前，Kumbier女士于1986年在科勒公司工作，在那里她在管道产品和发动机部门担任过各种职位。Kumbier女士自2018年起担任雅培实验室董事会成员。Kumbier女士是Teledyne Technologies Incorporated审计委员会和人事与薪酬委员会的成员。
- Michelle A. Kumbier,Senior Vice President and President, Turf & Consumer Products of Briggs & Stratton, LLC, a manufacturer and marketer of engines, batteries, and outdoor power equipment, since March 2022.Senior Vice President and Chief Operating Officer of Harley-Davidson Motor Company, a motorcycle and related products manufacturer, from 2017 to 2020.Senior Vice President of Motor Company Product and Operations of Harley-Davidson from 2015 to 2017.Held various other executive roles across Harley-Davidson, from 1997 to 2015.Held various positions at Kohler Company, maker of premium plumbing products, from 1986 to 1997.
- Paola Gonzalez
-
Paola Gonzalez 自 2018 年 1 月起担任消费品和专业产品制造商和营销商 Clorox 公司副总裁兼财务主管。2010 年至 2017 年担任 Clorox 财务、家庭和生活方式部门副总裁。财务副总裁，全球战略计划 从 2008 年到 2010 年，Clorox。自 1997 年加入 Clorox 以来，在整个 Clorox 担任过各种财务领导职务。在 Clorox 之前，曾在拉丁美洲的美国航空公司从事财务工作。
Paola Gonzalez,Vice President and Treasurer of The Clorox Company, a manufacturer and marketer of consumer and professional products, since January 2018.Vice President of Finance, Household and Lifestyle Segments of Clorox from 2010 to 2017.Vice President of Finance, Global Strategic Initiatives of Clorox from 2008 to 2010.Held various leadership roles in finance across Clorox since joining Clorox in 1997.Prior to Clorox, worked in finance for American Airlines in Latin America. - Paola Gonzalez 自 2018 年 1 月起担任消费品和专业产品制造商和营销商 Clorox 公司副总裁兼财务主管。2010 年至 2017 年担任 Clorox 财务、家庭和生活方式部门副总裁。财务副总裁，全球战略计划 从 2008 年到 2010 年，Clorox。自 1997 年加入 Clorox 以来，在整个 Clorox 担任过各种财务领导职务。在 Clorox 之前，曾在拉丁美洲的美国航空公司从事财务工作。
- Paola Gonzalez,Vice President and Treasurer of The Clorox Company, a manufacturer and marketer of consumer and professional products, since January 2018.Vice President of Finance, Household and Lifestyle Segments of Clorox from 2010 to 2017.Vice President of Finance, Global Strategic Initiatives of Clorox from 2008 to 2010.Held various leadership roles in finance across Clorox since joining Clorox in 1997.Prior to Clorox, worked in finance for American Airlines in Latin America.
- Claire Babineaux Fontenot
-
Claire Babineaux Fontenot，自2018年起担任美国饥饿救济慈善组织Feeding America的首席执行官。自2017年以来，他是CBF Consulting Group, LLC（一家商业咨询公司）的创始人。2014年至2017年，担任Walmart Inc.（一家经营超级中心、折扣百货商店和电子商务网站的跨国零售公司）的执行副总裁兼全球财务主管。2007年至2014年，担任Walmart高级副总裁兼首席税务官。2004年至2007年，担任Walmart审计和税收政策副总裁。从2018年到2019年，他担任Charah Solutions, Inc.的董事会成员。
Claire Babineaux Fontenot,Chief Executive Officer of Feeding America, a U.S. hunger-relief charitable organization, since 2018.Founder of CBF Consulting Group, LLC, a business consulting firm, since 2017.Executive Vice President and Global Treasurer of Walmart Inc., a multinational retail corporation operating supercenters, discount department stores, and eCommerce websites, from 2014 to 2017.Senior Vice President and Chief Tax Officer of Walmart, from 2007 to 2014.Vice President of Audits and Tax Policy of Walmart, from 2004 to 2007.Serves on the Board of Directors of New York Life Insurance Company and served on the Board of Directors of Charah Solutions, Inc. from 2018 to 2019. - Claire Babineaux Fontenot，自2018年起担任美国饥饿救济慈善组织Feeding America的首席执行官。自2017年以来，他是CBF Consulting Group, LLC（一家商业咨询公司）的创始人。2014年至2017年，担任Walmart Inc.（一家经营超级中心、折扣百货商店和电子商务网站的跨国零售公司）的执行副总裁兼全球财务主管。2007年至2014年，担任Walmart高级副总裁兼首席税务官。2004年至2007年，担任Walmart审计和税收政策副总裁。从2018年到2019年，他担任Charah Solutions, Inc.的董事会成员。
- Claire Babineaux Fontenot,Chief Executive Officer of Feeding America, a U.S. hunger-relief charitable organization, since 2018.Founder of CBF Consulting Group, LLC, a business consulting firm, since 2017.Executive Vice President and Global Treasurer of Walmart Inc., a multinational retail corporation operating supercenters, discount department stores, and eCommerce websites, from 2014 to 2017.Senior Vice President and Chief Tax Officer of Walmart, from 2007 to 2014.Vice President of Audits and Tax Policy of Walmart, from 2004 to 2007.Serves on the Board of Directors of New York Life Insurance Company and served on the Board of Directors of Charah Solutions, Inc. from 2018 to 2019.
- Robert J. Alpern
-
Robert J. Alpern，他担任少尉医学教授、内科教授和康涅狄格纽黑文耶鲁医学院院长。自2004年6月，他一直担任少尉医学教授、内科教授以及耶鲁大学医学院院长。从1998年7月至2004年6月，他担任得克萨斯大学西南医学中心的院长。他还担任AbbVie公司的董事，并担任 耶鲁 - 纽黑文医院的董事会董事。
Robert J. Alpern,is Ensign Professor of Medicine and Physiology and Professor of Internal Medicine and Cellular and Molecular Physiology at Yale School of Medicine. Dr. Alpern served as the Dean of Yale School of Medicine and Ensign Professor of Medicine and Professor of Internal Medicine at Yale School of Medicine from June 2004 to January 2020. From July 1998 to May 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical Center. Dr. Alpern served on the board of Yale-New Haven Hospital from October 2005 to January 2020. Dr. Alpern also serves as a director of Abbott Laboratories and Tricida, Inc. - Robert J. Alpern，他担任少尉医学教授、内科教授和康涅狄格纽黑文耶鲁医学院院长。自2004年6月，他一直担任少尉医学教授、内科教授以及耶鲁大学医学院院长。从1998年7月至2004年6月，他担任得克萨斯大学西南医学中心的院长。他还担任AbbVie公司的董事，并担任 耶鲁 - 纽黑文医院的董事会董事。
- Robert J. Alpern,is Ensign Professor of Medicine and Physiology and Professor of Internal Medicine and Cellular and Molecular Physiology at Yale School of Medicine. Dr. Alpern served as the Dean of Yale School of Medicine and Ensign Professor of Medicine and Professor of Internal Medicine at Yale School of Medicine from June 2004 to January 2020. From July 1998 to May 2004, Dr. Alpern was the Dean of The University of Texas Southwestern Medical Center. Dr. Alpern served on the board of Yale-New Haven Hospital from October 2005 to January 2020. Dr. Alpern also serves as a director of Abbott Laboratories and Tricida, Inc.
- William A. Osborn
-
William A. Osborn ，1995年10月至2009年11月，他担任北方信托公司多银行控股公司的主席。1995年至2007年，他担任北方信托公司多银行控股公司的首席执行官。2003年至2006年，他担任北方信托公司和北方信托公司（银行服务）的总裁。目前，他担任雅培公司和卡特彼勒公司的总监。在过去的几年里，他在北方信托公司担任过董事职位。
William A. Osborn was Chairman of Northern Trust Corporation from 1995 through 2009 and served as its Chief Executive Officer from 1995 through 2007. Mr. Osborn currently serves as a Director of Caterpillar Inc. and General Dynamics Corporation. Mr. Osborn served on the Board of Directors of Nicor, Inc. from 1999 to 2006 and on the Board of Directors of Tribune Company from 2001 to 2012. - William A. Osborn ，1995年10月至2009年11月，他担任北方信托公司多银行控股公司的主席。1995年至2007年，他担任北方信托公司多银行控股公司的首席执行官。2003年至2006年，他担任北方信托公司和北方信托公司（银行服务）的总裁。目前，他担任雅培公司和卡特彼勒公司的总监。在过去的几年里，他在北方信托公司担任过董事职位。
- William A. Osborn was Chairman of Northern Trust Corporation from 1995 through 2009 and served as its Chief Executive Officer from 1995 through 2007. Mr. Osborn currently serves as a Director of Caterpillar Inc. and General Dynamics Corporation. Mr. Osborn served on the Board of Directors of Nicor, Inc. from 1999 to 2006 and on the Board of Directors of Tribune Company from 2001 to 2012.
- Glenn F. Tilton
-
Glenn F. Tilton，他是JPMorgan Chase & Co. Chicago公司、Illinois Banking and Financial Services Company的中西部地区主席。他成为摩根大通公司（JPMorgan Chase & Co.）的中西部地区主席，以及其全公司执行委员会成员。从2010年10月到2012年12月，他也曾担任United Continental Holdings公司的董事会非执行董事。从2002年9月到2010年10月，他曾担任UAL Corporation（控股公司）的主席、总裁兼首席执行官，United Air Lines公司（航空运输公司，UAL Corporation的全资子公司）的主席兼首席执行官。他是AbbVie公司和Phillips 66公司的董事。他也曾任职于Lincoln National Corporation（从2002年到2007年）、TXU Corporation（从2005年到2007年）、Corning Incorporated公司（从2010年到2012年）、United Continental Holdings公司（从2001年到2013年）的董事会。
Glenn F. Tilton,service as Chairman and Chief Executive Officer of UAL Corporation, the parent company of United Airlines, as well as Chairman of the Midwest of JPMorgan Chase, has provided him with strong management experience overseeing complex multinational businesses operating in highly regulated industries as well as expertise in financial reporting, risk management, environmental issues, business transformations and capital markets, which assist in his oversight of Phillips 66's management team and financial strategy.He also provides Phillips 66 with extensive experience in the energy industry following a career spanning more than 30 years with Texaco, including serving as Chairman and Chief Executive Officer.He has significant experience with public policy and government affairs through his service on numerous councils and associations including the Chicago Council on Global Affairs, the U.S. Department of Transportation's Future of Aviation Advisory Committee, President Obama's White House Forum on Modernizing Government, and the President's Export Council; he has also served in Chair roles within the Airlines Trade Association and the Star Alliance.He has served as Phillips 66's Lead Independent Director since 2016, where he fulfills an important leadership function in the boardroom and provides an independent voice to the Chief Executive Officer and Executive Chairman in key Board and Company decisions.Mr. Tilton has been a leading participant in conversations with Phillips 66's shareholders in recent years, serving as a critical representative of Phillips 66 shareholders during discussions with the rest of the Board, and in turn representing the perspectives of the full Board in conversations with Phillips 66 shareholders.Mr. Tilton's current and past experiences in significant leadership roles at a variety of public company boards, including Lead Independent Director at AbbVie, Vice Chairman at Chevron, Chairman of United Continental Holdings following the merger between United and Continental Airlines, and a member of the Special Committee at TXU Corporation which negotiated the sale of the company as part of the then-largest leveraged buyout on record, provides him with deep knowledge of corporate governance and board oversight across a range of complex situations. - Glenn F. Tilton，他是JPMorgan Chase & Co. Chicago公司、Illinois Banking and Financial Services Company的中西部地区主席。他成为摩根大通公司（JPMorgan Chase & Co.）的中西部地区主席，以及其全公司执行委员会成员。从2010年10月到2012年12月，他也曾担任United Continental Holdings公司的董事会非执行董事。从2002年9月到2010年10月，他曾担任UAL Corporation（控股公司）的主席、总裁兼首席执行官，United Air Lines公司（航空运输公司，UAL Corporation的全资子公司）的主席兼首席执行官。他是AbbVie公司和Phillips 66公司的董事。他也曾任职于Lincoln National Corporation（从2002年到2007年）、TXU Corporation（从2005年到2007年）、Corning Incorporated公司（从2010年到2012年）、United Continental Holdings公司（从2001年到2013年）的董事会。
- Glenn F. Tilton,service as Chairman and Chief Executive Officer of UAL Corporation, the parent company of United Airlines, as well as Chairman of the Midwest of JPMorgan Chase, has provided him with strong management experience overseeing complex multinational businesses operating in highly regulated industries as well as expertise in financial reporting, risk management, environmental issues, business transformations and capital markets, which assist in his oversight of Phillips 66's management team and financial strategy.He also provides Phillips 66 with extensive experience in the energy industry following a career spanning more than 30 years with Texaco, including serving as Chairman and Chief Executive Officer.He has significant experience with public policy and government affairs through his service on numerous councils and associations including the Chicago Council on Global Affairs, the U.S. Department of Transportation's Future of Aviation Advisory Committee, President Obama's White House Forum on Modernizing Government, and the President's Export Council; he has also served in Chair roles within the Airlines Trade Association and the Star Alliance.He has served as Phillips 66's Lead Independent Director since 2016, where he fulfills an important leadership function in the boardroom and provides an independent voice to the Chief Executive Officer and Executive Chairman in key Board and Company decisions.Mr. Tilton has been a leading participant in conversations with Phillips 66's shareholders in recent years, serving as a critical representative of Phillips 66 shareholders during discussions with the rest of the Board, and in turn representing the perspectives of the full Board in conversations with Phillips 66 shareholders.Mr. Tilton's current and past experiences in significant leadership roles at a variety of public company boards, including Lead Independent Director at AbbVie, Vice Chairman at Chevron, Chairman of United Continental Holdings following the merger between United and Continental Airlines, and a member of the Special Committee at TXU Corporation which negotiated the sale of the company as part of the then-largest leveraged buyout on record, provides him with deep knowledge of corporate governance and board oversight across a range of complex situations.
- Nancy McKinstry
-
Nancy McKinstry，自2003年9月，她一直担任威科NV的首席执行官兼执行董事会主席。2001年6月，她担任执行董事会成员。她担任SANOMA公司的董事。她还担任罗德岛大学的顾问委员会、阿姆斯特丹金融学院咨询委员会、哥伦比亚大学商学院董事会、哈林顿传播和媒体学院顾问委员会的成员。2004年至2012年，她担任Telefonieaktiebolaget爱立信LM爱立信电话公司的董事。从2004年到2007年，她还担任MortgageIT控股公司的董事。威科集团NV、尔芬AAN巢穴Rijn、荷兰（全球信息，软件和服务提供商）的执行董事会主席 。
Nancy McKinstry,has been chief executive officer and chairman of the executive board (a board made up of solely management members, which is distinct from Wolters Kluwer's independent supervisory board) of Wolters Kluwer N.V. ("Wolters Kluwer"), a global professional information services and solutions company, since September 2003 and a member of its executive board since 2001. Before assuming her current position, Ms. McKinstry gained more than a decade of experience with Wolters Kluwer and its North American subsidiaries, serving as chief executive officer of CCH Legal Information Services for three years and as chief executive officer of operations in North America. Earlier in her career, she was a principal with Booz & Company (formerly Booz Allen Hamilton Inc.), focusing on media and technology.Ms. McKinstry is a director of Abbott Laboratories.Ms. McKinstry earned a Bachelor of Arts degree in Economics from the University of Rhode Island, Kingston and holds an MBA in Finance and Marketing from Columbia University. - Nancy McKinstry，自2003年9月，她一直担任威科NV的首席执行官兼执行董事会主席。2001年6月，她担任执行董事会成员。她担任SANOMA公司的董事。她还担任罗德岛大学的顾问委员会、阿姆斯特丹金融学院咨询委员会、哥伦比亚大学商学院董事会、哈林顿传播和媒体学院顾问委员会的成员。2004年至2012年，她担任Telefonieaktiebolaget爱立信LM爱立信电话公司的董事。从2004年到2007年，她还担任MortgageIT控股公司的董事。威科集团NV、尔芬AAN巢穴Rijn、荷兰（全球信息，软件和服务提供商）的执行董事会主席 。
- Nancy McKinstry,has been chief executive officer and chairman of the executive board (a board made up of solely management members, which is distinct from Wolters Kluwer's independent supervisory board) of Wolters Kluwer N.V. ("Wolters Kluwer"), a global professional information services and solutions company, since September 2003 and a member of its executive board since 2001. Before assuming her current position, Ms. McKinstry gained more than a decade of experience with Wolters Kluwer and its North American subsidiaries, serving as chief executive officer of CCH Legal Information Services for three years and as chief executive officer of operations in North America. Earlier in her career, she was a principal with Booz & Company (formerly Booz Allen Hamilton Inc.), focusing on media and technology.Ms. McKinstry is a director of Abbott Laboratories.Ms. McKinstry earned a Bachelor of Arts degree in Economics from the University of Rhode Island, Kingston and holds an MBA in Finance and Marketing from Columbia University.
- Michael F. Roman
-
Michael F. Roman自2017年7月起担任3M公司的首席运营官兼执行副总裁，直接负责3M的五个业务集团和公司的国际业务。 Roman先生于2014年6月至2017年7月担任3M公司工业业务集团执行副总裁。Roman先生于2013年5月至2014年6月担任公司业务发展高级副总裁。在此之前，他 2011年9月至2013年5月，他担任工业胶粘剂和胶带部门的副总裁兼总经理。罗曼先生还曾在全球范围内生活并领导3M业务，包括美国，欧洲和亚洲。 罗曼明尼苏达大学和南加州大学电子工程学士和硕士学位。
Michael F. Roman,is the Chairman of the Board and Chief Executive Officer of 3M Company since May 2019. Mr. Roman previously served as Chief Executive Officer from July 1, 2018 to May 14, 2019; Chief Operating Officer and Executive Vice President from July 1, 2017 to June 30, 2018 with direct responsibilities for 3M's five business groups and the Company's international operations. Mr. Roman previously served as Executive Vice President, Industrial Business Group, of 3M Company from June 2014 to July 2017. Mr. Roman served as the Company's Senior Vice President, Business Development, from May 2013 to June 2014. Prior to that, he was Vice President and General Manager of Industrial Adhesives and Tapes Division from September 2011 to May 2013. Mr. Roman also has lived in and led 3M businesses around the world, including the United States, Europe, and Asia. - Michael F. Roman自2017年7月起担任3M公司的首席运营官兼执行副总裁，直接负责3M的五个业务集团和公司的国际业务。 Roman先生于2014年6月至2017年7月担任3M公司工业业务集团执行副总裁。Roman先生于2013年5月至2014年6月担任公司业务发展高级副总裁。在此之前，他 2011年9月至2013年5月，他担任工业胶粘剂和胶带部门的副总裁兼总经理。罗曼先生还曾在全球范围内生活并领导3M业务，包括美国，欧洲和亚洲。 罗曼明尼苏达大学和南加州大学电子工程学士和硕士学位。
- Michael F. Roman,is the Chairman of the Board and Chief Executive Officer of 3M Company since May 2019. Mr. Roman previously served as Chief Executive Officer from July 1, 2018 to May 14, 2019; Chief Operating Officer and Executive Vice President from July 1, 2017 to June 30, 2018 with direct responsibilities for 3M's five business groups and the Company's international operations. Mr. Roman previously served as Executive Vice President, Industrial Business Group, of 3M Company from June 2014 to July 2017. Mr. Roman served as the Company's Senior Vice President, Business Development, from May 2013 to June 2014. Prior to that, he was Vice President and General Manager of Industrial Adhesives and Tapes Division from September 2011 to May 2013. Mr. Roman also has lived in and led 3M businesses around the world, including the United States, Europe, and Asia.
高管简历
中英对照 | 中文 | 英文- Robert Ford
Robert Ford，担任执行副总裁，负责医疗设备（2015年至今）、高级副总裁，负责糖尿病护理（2014年至2015年）、糖尿病护理贸易化运营副总裁（2008年至2014年）、公司职员（2008年）。
Robert Ford,Chairman of the Board and Chief Executive Officer of Abbott since December 2021.President and Chief Executive Officer of Abbott from March 2020 to December 2021.President and Chief Operating Officer of Abbott from 2018 to 2020.Executive Vice President, Medical Devices of Abbott from 2015 to 2018.Senior Vice President, Diabetes Care of Abbott from 2014 to 2015.Held various leadership roles across Abbott's Diagnostics, Nutrition, and Diabetes Care businesses in the U.S. and Latin America since joining Abbott in 1996.- Robert Ford，担任执行副总裁，负责医疗设备（2015年至今）、高级副总裁，负责糖尿病护理（2014年至2015年）、糖尿病护理贸易化运营副总裁（2008年至2014年）、公司职员（2008年）。
- Robert Ford,Chairman of the Board and Chief Executive Officer of Abbott since December 2021.President and Chief Executive Officer of Abbott from March 2020 to December 2021.President and Chief Operating Officer of Abbott from 2018 to 2020.Executive Vice President, Medical Devices of Abbott from 2015 to 2018.Senior Vice President, Diabetes Care of Abbott from 2014 to 2015.Held various leadership roles across Abbott's Diagnostics, Nutrition, and Diabetes Care businesses in the U.S. and Latin America since joining Abbott in 1996.
- Daniel Salvadori
Daniel Salvadori，2014年至今，他担任拉丁美洲建立药品高级副总裁。从2013年到2014年，他担任CFR Pharmaceuticals S.A.（拉丁美洲的制药公司）的拉丁美洲首席执行官。从2012年到2013年，他担任CFR Pharmaceuticals S.A.的复杂治疗部门执行总裁。从2010年到2012年，他担任 Sandoz Pharmaceuticals和Novartis AG （瑞士跨国制药公司）拉丁美洲销售和市场营销负责人。2014年他当选公司官员。
Daniel Salvadori,2021 to present — Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products.2017 to 2021 — Executive Vice President, Nutritional Products.Elected Corporate Officer — 2014.- Daniel Salvadori，2014年至今，他担任拉丁美洲建立药品高级副总裁。从2013年到2014年，他担任CFR Pharmaceuticals S.A.（拉丁美洲的制药公司）的拉丁美洲首席执行官。从2012年到2013年，他担任CFR Pharmaceuticals S.A.的复杂治疗部门执行总裁。从2010年到2012年，他担任 Sandoz Pharmaceuticals和Novartis AG （瑞士跨国制药公司）拉丁美洲销售和市场营销负责人。2014年他当选公司官员。
- Daniel Salvadori,2021 to present — Executive Vice President and Group President, Established Pharmaceuticals and Nutritional Products.2017 to 2021 — Executive Vice President, Nutritional Products.Elected Corporate Officer — 2014.
- Jared L. Watkin
Jared L. Watkin， 他担任糖尿病护理高级副总裁（2015年至今）、糖尿病护理技术运营部门副总裁（2010年到2015年）。2015年他当选公司官员。189．Roger Bird， 他担任U.S. Nutrition高级副总裁（2015年至今）、中国和中国香港 营养品部门副总裁兼总经理（2009年到2015年）。2015年他当选公司官员。
Jared L. Watkin,2015 to present — Senior Vice President, Diabetes Care.Elected Corporate Officer — 2015.- Jared L. Watkin， 他担任糖尿病护理高级副总裁（2015年至今）、糖尿病护理技术运营部门副总裁（2010年到2015年）。2015年他当选公司官员。189．Roger Bird， 他担任U.S. Nutrition高级副总裁（2015年至今）、中国和中国香港 营养品部门副总裁兼总经理（2009年到2015年）。2015年他当选公司官员。
- Jared L. Watkin,2015 to present — Senior Vice President, Diabetes Care.Elected Corporate Officer — 2015.
- Joseph Manning
Joseph Manning，2017年至今-国际营养高级副总裁。2015年至2017年-亚太地区营养副总裁。2014年至2015年-印度尼西亚营养产品总经理。当选公司总监-2015年。
Joseph Manning,2021 to present — Executive Vice President, Nutritional Products.2017 to 2021 — Senior Vice President, International Nutrition.Elected Corporate Officer — 2015.- Joseph Manning，2017年至今-国际营养高级副总裁。2015年至2017年-亚太地区营养副总裁。2014年至2015年-印度尼西亚营养产品总经理。当选公司总监-2015年。
- Joseph Manning,2021 to present — Executive Vice President, Nutritional Products.2017 to 2021 — Senior Vice President, International Nutrition.Elected Corporate Officer — 2015.
- Sammy Karam
Sammy Karam，2019年至今-新兴市场成熟药品高级副总裁。2014年至2019年-成熟药品全球营销商业执行部门副总裁。当选公司官员-2019年。
Sammy Karam,2019 to present — Senior Vice President, Established Pharmaceuticals, Emerging Markets.2014 to 2019 — Divisional Vice President, Global Marketing Commercial Execution, Established Pharmaceuticals.Elected Corporate Officer — 2019.- Sammy Karam，2019年至今-新兴市场成熟药品高级副总裁。2014年至2019年-成熟药品全球营销商业执行部门副总裁。当选公司官员-2019年。
- Sammy Karam,2019 to present — Senior Vice President, Established Pharmaceuticals, Emerging Markets.2014 to 2019 — Divisional Vice President, Global Marketing Commercial Execution, Established Pharmaceuticals.Elected Corporate Officer — 2019.
- Michael J. Pederson
Michael J. Pederson，2019年至今-电生理学和心力衰竭高级副总裁。2017年至2019年-心律失常和心力衰竭高级副总裁。2015年至2017年-雅培电生理学部门副总裁兼总经理。2011年至2015年- VytronUS，Inc.是一家专注于开发电生理技术的医疗设备公司首席执行官。当选公司首席执行官-2017年。
Michael J. Pederson,2021 to present — Senior Vice President, Electrophysiology.2019 to 2021 — Senior Vice President, Electrophysiology and Heart Failure.2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.Elected Corporate Officer — 2017.- Michael J. Pederson，2019年至今-电生理学和心力衰竭高级副总裁。2017年至2019年-心律失常和心力衰竭高级副总裁。2015年至2017年-雅培电生理学部门副总裁兼总经理。2011年至2015年- VytronUS，Inc.是一家专注于开发电生理技术的医疗设备公司首席执行官。当选公司首席执行官-2017年。
- Michael J. Pederson,2021 to present — Senior Vice President, Electrophysiology.2019 to 2021 — Senior Vice President, Electrophysiology and Heart Failure.2017 to 2019 — Senior Vice President, Cardiac Arrhythmias and Heart Failure.Elected Corporate Officer — 2017.
- Alejandro D. Wellisch
Alejandro D. Wellisch，2017年至今-拉丁美洲成熟制药公司高级副总裁。2014年至2017年-阿根廷成熟制药公司阿根廷，玻利维亚，巴拉圭和乌拉圭总经理。当选公司官员-2017年。
Alejandro D. Wellisch,2017 to present — Senior Vice President, Established Pharmaceuticals, Latin America.- Alejandro D. Wellisch，2017年至今-拉丁美洲成熟制药公司高级副总裁。2014年至2017年-阿根廷成熟制药公司阿根廷，玻利维亚，巴拉圭和乌拉圭总经理。当选公司官员-2017年。
- Alejandro D. Wellisch,2017 to present — Senior Vice President, Established Pharmaceuticals, Latin America.
- John F. Ginascol
John F. Ginascol， 2019年至今-Core Diagnostics执行副总裁。2008年至2019年-供应链营养副总裁，当选公司总监-2008年。
John F. Ginascol,2019 to present — Executive Vice President, Core Diagnostics.2008 to 2019 — Vice President, Nutrition, Supply Chain.Elected Corporate Officer — 2008.- John F. Ginascol， 2019年至今-Core Diagnostics执行副总裁。2008年至2019年-供应链营养副总裁，当选公司总监-2008年。
- John F. Ginascol,2019 to present — Executive Vice President, Core Diagnostics.2008 to 2019 — Vice President, Nutrition, Supply Chain.Elected Corporate Officer — 2008.
- Mary K. Moreland
Mary K. Moreland2019年至今-人力资源执行副总裁。2013年至2019年-薪酬，福利和人力资源并购部门副总裁。当选公司总监-2019年。
Mary K. Moreland,2019 to present — Executive Vice President, Human Resources.2013 to 2019 — Divisional Vice President, Compensation, Benefits and HR M&A.Elected Corporate Officer — 2019.- Mary K. Moreland2019年至今-人力资源执行副总裁。2013年至2019年-薪酬，福利和人力资源并购部门副总裁。当选公司总监-2019年。
- Mary K. Moreland,2019 to present — Executive Vice President, Human Resources.2013 to 2019 — Divisional Vice President, Compensation, Benefits and HR M&A.Elected Corporate Officer — 2019.
- Andrea Wainer
Andrea Wainer，2019年至今-快速与分子诊断学执行副总裁。2015年至2019年-Molecular Diagnostics副总裁当选公司官员-2015年。
Andrea Wainer,2019 to present — Executive Vice President, Rapid and Molecular Diagnostics.2015 to 2019 — Vice President, Molecular Diagnostics.Elected Corporate Officer — 2015.- Andrea Wainer，2019年至今-快速与分子诊断学执行副总裁。2015年至2019年-Molecular Diagnostics副总裁当选公司官员-2015年。
- Andrea Wainer,2019 to present — Executive Vice President, Rapid and Molecular Diagnostics.2015 to 2019 — Vice President, Molecular Diagnostics.Elected Corporate Officer — 2015.
- Michael D. Dale
Michael D. Dale， 2019年至今-结构心公司高级副总裁。2017年至2019年-结构心公司副总裁。2016年至2017年-结构心公司部门副总裁兼总经理。2014年至2016年-总裁兼首席执行官， GI Dynamics，Inc.是一家医疗器械公司，致力于开发胃肠道疗法。2017年当选公司总监。
Michael D. Dale,2019 to present — Senior Vice President, Structural Heart.2017 to 2019 — Vice President, Structural Heart.Elected Corporate Officer — 2017.- Michael D. Dale， 2019年至今-结构心公司高级副总裁。2017年至2019年-结构心公司副总裁。2016年至2017年-结构心公司部门副总裁兼总经理。2014年至2016年-总裁兼首席执行官， GI Dynamics，Inc.是一家医疗器械公司，致力于开发胃肠道疗法。2017年当选公司总监。
- Michael D. Dale,2019 to present — Senior Vice President, Structural Heart.2017 to 2019 — Vice President, Structural Heart.Elected Corporate Officer — 2017.
- Randel W. Woodgrift
Randel W. Woodgrift，2019年至今-CRM。2017年至2019年高级副总裁-心血管和神经调节全球运营副总裁。2015年至2017年-Abbott Vascular运营和研发副总裁，当选公司总监-2015年。
Randel W. Woodgrift,2019 to present — Senior Vice President, Cardio Rhythm Management.2017 to 2019 — Vice President, Global Operations, Cardiovascular and Neuromodulation.Elected Corporate Officer — 2015.- Randel W. Woodgrift，2019年至今-CRM。2017年至2019年高级副总裁-心血管和神经调节全球运营副总裁。2015年至2017年-Abbott Vascular运营和研发副总裁，当选公司总监-2015年。
- Randel W. Woodgrift,2019 to present — Senior Vice President, Cardio Rhythm Management.2017 to 2019 — Vice President, Global Operations, Cardiovascular and Neuromodulation.Elected Corporate Officer — 2015.
- Gregory A. Ahlberg
Gregory A. Ahlberg，2020年至今，商业运营部核心实验室诊断高级副总裁。2017年至2020年欧洲、中东和非洲商业运营部诊断副总裁。2012年至2017年雅培诊断部美国分部副总裁。2017年当选雅培公司高管。
Gregory A. Ahlberg,2020 to present — Senior Vice President, Core Laboratory Diagnostics, Commercial Operations.2017 to 2020 —Vice President, Diagnostics, Commercial Operations, Europe, Middle East and Africa.Elected Corporate Officer — 2017.- Gregory A. Ahlberg，2020年至今，商业运营部核心实验室诊断高级副总裁。2017年至2020年欧洲、中东和非洲商业运营部诊断副总裁。2012年至2017年雅培诊断部美国分部副总裁。2017年当选雅培公司高管。
- Gregory A. Ahlberg,2020 to present — Senior Vice President, Core Laboratory Diagnostics, Commercial Operations.2017 to 2020 —Vice President, Diagnostics, Commercial Operations, Europe, Middle East and Africa.Elected Corporate Officer — 2017.
- Philip P. Boudreau
Philip P. Boudreau，2020年至今，财务副总裁兼财务总监。2017年至2020年，医疗器械部门副总裁兼财务总监。2012年至2017年，医疗点部门副总裁兼财务总监兼商业支持。2020年，当选雅培公司高管。
Philip P. Boudreau,2020 to present — Vice President, Finance and Controller.2017 to 2020 — Divisional Vice President, Controller, Medical Devices.Elected Corporate Officer — 2020.- Philip P. Boudreau，2020年至今，财务副总裁兼财务总监。2017年至2020年，医疗器械部门副总裁兼财务总监。2012年至2017年，医疗点部门副总裁兼财务总监兼商业支持。2020年，当选雅培公司高管。
- Philip P. Boudreau,2020 to present — Vice President, Finance and Controller.2017 to 2020 — Divisional Vice President, Controller, Medical Devices.Elected Corporate Officer — 2020.
- Christopher J. Calamari
Christopher J. Calamari，现任美国营养副高级副总裁。2017至2021 -副总裁，儿科营养学。2014年至2017年——儿科营养部门副总裁兼总经理。当选公司高管——2017年。
Christopher J. Calamari,2021 to present — Senior Vice President, U.S. Nutrition.2017 to 2021 — Vice President, Pediatric Nutrition.Elected Corporate Officer — 2017.- Christopher J. Calamari，现任美国营养副高级副总裁。2017至2021 -副总裁，儿科营养学。2014年至2017年——儿科营养部门副总裁兼总经理。当选公司高管——2017年。
- Christopher J. Calamari,2021 to present — Senior Vice President, U.S. Nutrition.2017 to 2021 — Vice President, Pediatric Nutrition.Elected Corporate Officer — 2017.
- Fernando Mateus
Fernando Mateus，现任国际营养副总裁。2018至2021 -副总裁，欧里萨，雅培国际营养。2016年至2018年——Exeltis USA，Inc.首席执行官，Exeltis USA，Inc.是一家专注于呼吸、皮肤和内分泌学的女性健康公司Exeltis的子公司。当选公司官员- 2021。
Fernando Mateus,2021 to present — Senior Vice President, International Nutrition.2018 to 2021 — Divisional Vice President, EURISA, Abbott International Nutrition.2016 to 2018 — Chief Executive Officer, Exeltis USA, Inc. (a subsidiary of Exeltis, a women's health company focused on respiratory, dermatology, and endocrinology).Elected Corporate Officer — 2021.- Fernando Mateus，现任国际营养副总裁。2018至2021 -副总裁，欧里萨，雅培国际营养。2016年至2018年——Exeltis USA，Inc.首席执行官，Exeltis USA，Inc.是一家专注于呼吸、皮肤和内分泌学的女性健康公司Exeltis的子公司。当选公司官员- 2021。
- Fernando Mateus,2021 to present — Senior Vice President, International Nutrition.2018 to 2021 — Divisional Vice President, EURISA, Abbott International Nutrition.2016 to 2018 — Chief Executive Officer, Exeltis USA, Inc. (a subsidiary of Exeltis, a women's health company focused on respiratory, dermatology, and endocrinology).Elected Corporate Officer — 2021.
- Louis H. Morrone
Louis H. Morrone，现任高级副总裁，快速诊断。2017至2021 -副总裁输血医学。2015年至2017年——输血医学部门副总裁兼总经理。当选公司高管——2017年。
Louis H. Morrone,2021 to present — Senior Vice President, Rapid Diagnostics.2017 to 2021 — Vice President, Transfusion Medicine.Elected Corporate Officer — 2017.- Louis H. Morrone，现任高级副总裁，快速诊断。2017至2021 -副总裁输血医学。2015年至2017年——输血医学部门副总裁兼总经理。当选公司高管——2017年。
- Louis H. Morrone,2021 to present — Senior Vice President, Rapid Diagnostics.2017 to 2021 — Vice President, Transfusion Medicine.Elected Corporate Officer — 2017.
- Julie L. Tyler
Julie L. Tyler，现任高级副总裁，Abbott Vascular。2021年4月至2021年7月-美国商务部ADC副总裁。2019至2021 -副总裁，全球营销，AVD。2017年至2019年——AVD美国销售和市场营销部副总裁。当选公司官员- 2021。
Julie L. Tyler,2021 to present — Senior Vice President, Abbott Vascular.April 2021 to July 2021 — Divisional Vice President, U.S. Commercial, Abbott Diabetes Care.2019 to 2021 — Divisional Vice President, Global Marketing, Abbott Vascular.2017 to 2019 — Divisional Vice President, U.S. Sales and Marketing Endovascular, Abbott Vascular.Elected Corporate Officer — 2021.- Julie L. Tyler，现任高级副总裁，Abbott Vascular。2021年4月至2021年7月-美国商务部ADC副总裁。2019至2021 -副总裁，全球营销，AVD。2017年至2019年——AVD美国销售和市场营销部副总裁。当选公司官员- 2021。
- Julie L. Tyler,2021 to present — Senior Vice President, Abbott Vascular.April 2021 to July 2021 — Divisional Vice President, U.S. Commercial, Abbott Diabetes Care.2019 to 2021 — Divisional Vice President, Global Marketing, Abbott Vascular.2017 to 2019 — Divisional Vice President, U.S. Sales and Marketing Endovascular, Abbott Vascular.Elected Corporate Officer — 2021.
- John A. McCoy, Jr.
John A. McCoy, Jr.，自2021年起担任雅培副总裁兼财务主管，并于2018年至2021年担任快速诊断部门副总裁兼财务总监，并于2017年至2018年担任财务共享服务部门副总裁。他于2017年加入雅培，并于2021年成为公司官员。加入雅培之前，他曾担任Baxalta Incorporated的高级副总裁兼公司财务总监（2015年至2017年）。
John A. McCoy, Jr.,has served as Abbott's Vice President, Treasurer since 2021, and served as Divisional Vice President, Controller, Rapid Diagnostics from 2018 to 2021 and as Divisional Vice President, Financial Shared Services from 2017 to 2018. He joined Abbott in 2017 and became a corporate officer in 2021. Prior to joining Abbott, Mr. McCoy served as Senior Vice President and Corporate Controller at Baxalta Incorporated from 2015 to 2017.- John A. McCoy, Jr.，自2021年起担任雅培副总裁兼财务主管，并于2018年至2021年担任快速诊断部门副总裁兼财务总监，并于2017年至2018年担任财务共享服务部门副总裁。他于2017年加入雅培，并于2021年成为公司官员。加入雅培之前，他曾担任Baxalta Incorporated的高级副总裁兼公司财务总监（2015年至2017年）。
- John A. McCoy, Jr.,has served as Abbott's Vice President, Treasurer since 2021, and served as Divisional Vice President, Controller, Rapid Diagnostics from 2018 to 2021 and as Divisional Vice President, Financial Shared Services from 2017 to 2018. He joined Abbott in 2017 and became a corporate officer in 2021. Prior to joining Abbott, Mr. McCoy served as Senior Vice President and Corporate Controller at Baxalta Incorporated from 2015 to 2017.
- John M. Capek
John M. Capek，2007年--至今，担任负责医疗器械的执行副总裁。2006年，当选为委企业主管。
John M. Capek,2015 to present — Executive Vice President, Ventures.Elected Corporate Officer — 2006.- John M. Capek，2007年--至今，担任负责医疗器械的执行副总裁。2006年，当选为委企业主管。
- John M. Capek,2015 to present — Executive Vice President, Ventures.Elected Corporate Officer — 2006.
- Hubert L. Allen
Hubert L. Allen，2013年--至今，担任执行副总裁兼法律总顾问兼秘书。2010年至2012年，担任负责设立医药的部门副总裁兼助理总法律顾问。2009年至2010年，担任负责专有制药的部门副总裁兼助理法律总顾问。2007年至2009年，担任雅培营养法律科长。2012年，当选为企业主管。
Hubert L. Allen,2013 to present — Executive Vice President, General Counsel and Secretary.Elected Corporate Officer — 2012.- Hubert L. Allen，2013年--至今，担任执行副总裁兼法律总顾问兼秘书。2010年至2012年，担任负责设立医药的部门副总裁兼助理总法律顾问。2009年至2010年，担任负责专有制药的部门副总裁兼助理法律总顾问。2007年至2009年，担任雅培营养法律科长。2012年，当选为企业主管。
- Hubert L. Allen,2013 to present — Executive Vice President, General Counsel and Secretary.Elected Corporate Officer — 2012.
- Robert E. Funck
Robert E. Funck，2013年--至今，担任副总裁兼主管。2009年至2013年，担任副总裁、首席道德与合规官。2007年至2009年，担任负责内部审计的副总裁。2005年，当选为公司主管。
Robert E. Funck,2020 to present — Executive Vice President, Finance and Chief Financial Officer.2018 to 2020 — Senior Vice President, Finance and Controller.2013 to 2018 — Vice President, Controller.Elected Corporate Officer — 2005.- Robert E. Funck，2013年--至今，担任副总裁兼主管。2009年至2013年，担任副总裁、首席道德与合规官。2007年至2009年，担任负责内部审计的副总裁。2005年，当选为公司主管。
- Robert E. Funck,2020 to present — Executive Vice President, Finance and Chief Financial Officer.2018 to 2020 — Senior Vice President, Finance and Controller.2013 to 2018 — Vice President, Controller.Elected Corporate Officer — 2005.
- Lisa D. Earnhardt
Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
Lisa D. Earnhardt,2019 to present — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019.- Lisa D. Earnhardt从2008年3月开始担任Abbott Laboratories 总裁兼首席执行官，并担任董事，加入Abbott Laboratories 前，从2006年6月到2008年1月，Earnhardt女士担任波士顿科技公司（Boston Scientific）的心脏病外科手术部门的总裁直到其被出售给洁定集团（Getinge Group），前者以前叫美国佳滕公司（Guidant Corporation）或Guidant。从1996年8月到2006年4月，Earnhardt女士在Guidant任职，担任多个销售与市场部的领导职位。Earnhardt女士从2011年开始担任Kensey Nash的董事直到其于2012年被Royal DSM NA收购，前者是一家上市公司，她在该公司担任董事会的提名与治理和审计委员会委员。Earnhardt女士担任凯洛格商学院校友理事会（Kellogg Alumni Council）的主席。Earnhardt女士在西北大学凯洛格管理学院（Northwestern’s Kellogg School of Management ）获得工商管理硕士学位，并在斯坦福大学（Stanford University）获得工业工程理学士学位。
- Lisa D. Earnhardt,2019 to present — Executive Vice President, Medical Devices.2008 to 2019 — President, CEO, and Director, Intersect ENT (a medical technology company focused on developing treatments for ear, nose and throat conditions).Elected Corporate Officer — 2019.